Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Moderna just received fantastic news.

The company's pending vaccine approvals could help the stock continue its rise.

Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...

Moderna shares were up 13% Friday after the biotech company revealed a new effort to make a treatment for autoimmune ...